Table 2.
Placebo period (D1–D2) | Single-dose period (D15–D16) | Repeated-dose period (D22–D30) | |||||||
---|---|---|---|---|---|---|---|---|---|
n | (%) | e | n | (%) | e | n | (%) | e | |
Dry pharynx | 4 | 36 | 7 | ||||||
Sore throat | 8 | 73 | 22 | ||||||
Throat burning | 4 | 36 | 12 | ||||||
Headache | 5 | 45 | 8 | ||||||
Jaw pain | 1 | 9 | 1 | ||||||
Neck pain | 2 | 18 | 3 | ||||||
Dizziness | 3 | 27 | 3 | 2 | 18 | 5 | |||
Poor sleep | 4 | 36 | 4 | ||||||
Palpitation | 2 | 18 | 2 | ||||||
Chest stuffiness | 3 | 27 | 5 | ||||||
Fatigue | 1 | 9 | 1 | ||||||
Nausea | 1 | 9 | 1 | ||||||
Skin needling sensation | 3 | 27 | 3 | ||||||
Skin burning sensation | 3 | 27 | 8 | ||||||
Limb numbness | 4 | 36 | 9 | ||||||
Limb pain | 1 | 9 | 1 | ||||||
Thirsty | 1 | 9 | 1 | ||||||
ALT | 4 | 36 | 8 | ||||||
AST | 4 | 36 | 8 |
n, Number of subjects; e, number of adverse events; %, proportion of subjects having the event.